Hormone receptor-positive adenoid cystic carcinoma of the breast with cross-modality imaging discrepancy: a case report and literature review.
- 1Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
- 2Department of Emergency Surgery, The First Hospital of Jilin University, Changchun, China.
Abstract
Primary adenoid cystic carcinoma of the breast (ACCB) is a rare salivary gland-type malignancy characterized by biphasic luminal epithelial and myoepithelial/basal differentiation. Although most ACCBs exhibit a triple-negative phenotype, hormone receptor-positive tumors occur, and evidence guiding endocrine therapy is limited. A 42-year-old woman presented with a gradually enlarging right breast mass. Ultrasonography and MRI were suspicious for malignancy (BI-RADS 4B and BI-RADS MRI category 5), whereas diagnostic mammography showed focal increased glandular density (BI-RADS 0) and benign punctate calcifications (BI-RADS 2). Core needle biopsy showed cribriform architecture, and immunohistochemistry demonstrated expression of CK7, CD117, and p63, supporting a diagnosis of ACCB. The biopsy showed estrogen receptor expression in 10%-20% of tumor cells, progesterone receptor expression in approximately 5%, and a HER2 score of 0. The patient underwent right mastectomy and sentinel lymph node biopsy. The resection specimen confirmed a 3.0 cm ACCB with predominantly cribriform architecture and additional solid growth, with ER and PR each expressed in approximately 30% of tumor cells, a HER2 IHC score of 0, and a negative sentinel lymph node [pT2 pN0(sn)]. She completed 5 years of adjuvant tamoxifen therapy. At the last follow-up, approximately 73 months after surgery, no local, regional, or distant recurrence was detected. This case highlights the value of integrating histomorphology and immunohistochemical findings when imaging findings differ across modalities and illustrates the immunophenotypic heterogeneity of ACCB. The recurrence-free outcome provides additional follow-up information for hormone receptor-positive ACCB but cannot establish benefit from endocrine therapy; individualized treatment and long-term surveillance remain warranted.
Related
- Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review
- Facial pruritus and stiffness as the initial manifestations of glycine receptor antibody-positive progressive encephalomyelitis with rigidity and myoclonus: a case report and literature review
- Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translational framework focused on invasive ductal carcinoma with gastric metastasis.
- A systematic literature review on the effects of exercise on human Toll-like receptor expression
- Synchronous laryngeal squamous cell carcinoma and papillary urothelial carcinoma of the bladder: a case report and literature review
BibTeX
@article{song2026hormone,
title = {{Hormone receptor-positive adenoid cystic carcinoma of the breast with cross-modality imaging discrepancy: a case report and literature review.}},
author = {Yunkuan Song and Yuezu He and Lu Peng and Fengjiang Qu and Sijie Li},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1966105},
url = {https://europepmc.org/article/MED/42948127},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hormone receptor-positive adenoid cystic carcinoma of the breast with cross-modality imaging discrepancy: a case report and literature review.
AU - Yunkuan Song
AU - Yuezu He
AU - Lu Peng
AU - Fengjiang Qu
AU - Sijie Li
PY - 2026
DA - 2026/10/13
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1966105
UR - https://europepmc.org/article/MED/42948127
AB - Primary adenoid cystic carcinoma of the breast (ACCB) is a rare salivary gland-type malignancy characterized by biphasic luminal epithelial and myoepithelial/basal differentiation. Although most ACCBs exhibit a triple-negative phenotype, hormone receptor-positive tumors occur, and evidence guiding endocrine therapy is limited. A 42-year-old woman presented with a gradually enlarging right breast mass. Ultrasonography and MRI were suspicious for malignancy (BI-RADS 4B and BI-RADS MRI category 5), whereas diagnostic mammography showed focal increased glandular density (BI-RADS 0) and benign punctate calcifications (BI-RADS 2). Core needle biopsy showed cribriform architecture, and immunohistochemistry demonstrated expression of CK7, CD117, and p63, supporting a diagnosis of ACCB. The biopsy showed estrogen receptor expression in 10%-20% of tumor cells, progesterone receptor expression in approximately 5%, and a HER2 score of 0. The patient underwent right mastectomy and sentinel lymph node biopsy. The resection specimen confirmed a 3.0 cm ACCB with predominantly cribriform architecture and additional solid growth, with ER and PR each expressed in approximately 30% of tumor cells, a HER2 IHC score of 0, and a negative sentinel lymph node [pT2 pN0(sn)]. She completed 5 years of adjuvant tamoxifen therapy. At the last follow-up, approximately 73 months after surgery, no local, regional, or distant recurrence was detected. This case highlights the value of integrating histomorphology and immunohistochemical findings when imaging findings differ across modalities and illustrates the immunophenotypic heterogeneity of ACCB. The recurrence-free outcome provides additional follow-up information for hormone receptor-positive ACCB but cannot establish benefit from endocrine therapy; individualized treatment and long-term surveillance remain warranted.
SN - 2296-858X
ER -